Background: The high-prevalence antigen Jr(a) is carried on the ATP-binding cassette transporter ABCG2. The ABCG2 gene consists of 16 exons and its translation start codon is located on the second exon. Although the occurrence of the Jr(a-) phenotype is rare, several ABCG2 null alleles have been reported. We report a new ABCG2 null allele having a large deletion in this study.

Study Design And Methods: The Jr(a) status was determined by standard serologic tests and genomic DNA was isolated from whole blood. Exons 1 to 16 and the 5'-untranslated region of the ABCG2 gene were analyzed by polymerase chain reaction and sequencing. Expression of the ABCG2 protein on red blood cells was examined by immunoblotting.

Results: A Jr(a-) blood donor had a novel allele having a 27-kb deletion including noncoding Exon 1 and the promoter region of ABCG2, and the donor was apparently homozygous for the allele. In addition, we found three more individuals having heterozygosity for the same allele, with ABCG2*01N.01 having c.376C>T (p.Q126X), but did not find the allele having the 27-kb deletion in 3000 Jr(a+) individuals. Immunoblotting revealed that the ABCG2 protein was not found to be expressed in the individual with homozygosity for the ABCG2 27-kb deleted and in two individuals with an ABCG2 27-kb deleted/ABCG2*01N.01 genotype, which indirectly allows to conclude that the 27-kb deletion is responsible for a null ABCG2 allele.

Conclusion: We first identified an ABCG2 null allele (provisional ISBT allele number ABCG2*01N.23) having a large deletion including the promoter region.

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.12969DOI Listing

Publication Analysis

Top Keywords

abcg2 null
16
27-kb deletion
16
abcg2
13
null allele
12
allele 27-kb
12
deletion including
12
promoter region
12
allele
8
including promoter
8
jra- phenotype
8

Similar Publications

Genotype Analysis of the JR Blood Group in an East Asian Population Using Tetra-Primer ARMS-PCR.

Ann Clin Lab Sci

July 2024

Department of Laboratory Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea

Objective: The JR blood group system, officially designated ISBT JR 032, consists of a single antigen called Jr. This is a high frequency antigen in most populations. The Jr(a-) phenotype is more prevalent in Japanese and Asian populations.

View Article and Find Full Text PDF

The Jra antigen, the only antigen within the JR blood group system, is a high-prevalence red blood cell (RBC) antigen found in over 99 % of the global population. An induced pluripotent stem cell line (YUCMi020-A) was generated from peripheral blood drawn from a Jr(a-) phenotype individual, who was homozygous for a null mutation of ABCG2*01N.01 (rs72552713, c.

View Article and Find Full Text PDF

Background: Null phenotypes are characterized by complete absence of all antigens within a blood group system and caused by null variants (e.g., nonsense, frameshift, initiation codon, and canonical splice site variants) in the genes encoding the antigens.

View Article and Find Full Text PDF

The environmental toxicant cadmium (Cd) impairs the growth of rodents and humans in utero which in turn heightens susceptibility to diseases later in life. We previously demonstrated that the maternal-facing efflux transporter, breast cancer resistance protein (human BCRP/ABCG2, mouse Bcrp/Abcg2) confers resistance against Cd toxicity in human trophoblasts. In the current study, we sought to determine whether the absence of Bcrp alters the fetoplacental disposition and toxicity of Cd in mice.

View Article and Find Full Text PDF
Article Synopsis
  • Deletions or mutations in the PTEN gene are common in glioblastoma (GBM) and lead to issues with DNA damage repair; this study investigates whether PTEN deficiency creates a weakness against combined DNA damage and repair suppression using specific inhibitors.
  • Researchers treated different GBM cell lines with the drug LMP400 (a TOP1 inhibitor) alone and with either PARP inhibitors (Olaparib or Niraparib) and found that PTEN-null cells are significantly more sensitive to this treatment.
  • The combination of LMP400 and Niraparib not only increases cell death in PTEN-deficient glioma cells but also shows promise in animal models for penetrating the blood-brain barrier and improving survival, supporting the
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!